EIE: Efficient Inference Engine on Compressed Deep Neural Network

State-of-the-art deep neural networks (DNNs) have hundreds of millions of connections and are both computationally and memory intensive, making them difficult to deploy on embedded systems with limited hardware resources and power budgets. While custom hardware helps the computation, fetching weights from DRAM is two orders of magnitude more expensive than ALU operations, and dominates the required power. Previously proposed 'Deep Compression' makes it possible to fit large DNNs (AlexNet and VGGNet) fully in on-chip SRAM. This compression is achieved by pruning the redundant connections and having multiple connections share the same weight. We propose an energy efficient inference engine (EIE) that performs inference on this compressed network model and accelerates the resulting sparse matrix-vector multiplication with weight sharing. Going from DRAM to SRAM gives EIE 120x energy saving; Exploiting sparsity saves 10x; Weight sharing gives 8x; Skipping zero activations from ReLU saves another 3x. Evaluated on nine DNN benchmarks, EIE is 189x and 13x faster when compared to CPU and GPU implementations of the same DNN without compression. EIE has a processing power of 102GOPS/s working directly on a compressed network, corresponding to 3TOPS/s on an uncompressed network, and processes FC layers of AlexNet at 1.88x10^4 frames/sec with a power dissipation of only 600mW. It is 24,000x and 3,400x more energy efficient than a CPU and GPU respectively. Compared with DaDianNao, EIE has 2.9x, 19x and 3x better throughput, energy efficiency and area efficiency.Comment: External Links: TheNextPlatform: http://goo.gl/f7qX0L ; O'Reilly: https://goo.gl/Id1HNT ; Hacker News: https://goo.gl/KM72SV ; Embedded-vision: http://goo.gl/joQNg8 ; Talk at NVIDIA GTC'16: http://goo.gl/6wJYvn ; Talk at Embedded Vision Summit: https://goo.gl/7abFNe ; Talk at Stanford University: https://goo.gl/6lwuer. Published as a conference paper in ISCA 201

Genomic analysis quantifies pyroptosis in the immune microenvironment of HBV-related hepatocellular carcinoma

Pyroptosis, a way of pro-inflammatory death, plays a significant part in the tumor microenvironment (TME). A recent study has shown that the hepatitis C virus changes the TME by inducing pyroptosis against hepatocellular carcinoma (HCC). However, compared to TME in hepatitis C virus-infected HCC, the exploration of immune characteristics and response to immunotherapy associated with the pyroptosis phenotype is still insufficient in hepatitis B virus-related HCC (HBV-HCC). Our study constructed pyroptosis-score (PYS) via principal-component analysis (PCA) to unveil the link between pyroptosis and tumor immunity in 369 HBV-HCC patients. Compared with the low-PYS group, subjects with higher PYS were associated with poor prognosis but were more susceptible to anti-PD-L1 treatment. In addition, we found that PYS can serve independently as a prognostic factor for HBV-HCC, making it possible for us to identify specific small molecule drugs with a potential value in inhibiting tumors via targeting pyroptosis. Also, the target genes predicted by the Weighted gene co-expression network analysis (WGCNA) and pharmacophore model were enriched in the HIF-1 signaling pathway and NF-kB transcription factor activity, which were related to the mechanism of inflammation-driven cancer. The PYS is extremely important in predicting prognosis and responses to immunotherapy. New treatment strategies for inflammation-driven cancers may be found by targeting pyroptosis

Probiotic Escherichia coli Nissle 1917-derived outer membrane vesicles modulate the intestinal microbiome and host gut-liver metabolome in obese and diabetic mice

IntroductionObesity and diabetes are common chronic metabolic disorders which can cause an imbalance of the intestinal flora and gut-liver metabolism. Several studies have shown that probiotics, including Escherichia coli Nissle 1917 (EcN), promote microbial balance and metabolic health. However, there are no studies on how EcN outer membrane vesicles (EcN-OMVs) influence the intestinal microflora and affect the metabolic disorders of obesity and diabetes.MethodsIn this study, we evaluated the effects of EcN-OMVs on high-fat diet (HFD)-induced obesity and HFD + streptozotocin (STZ)-induced diabetes.ResultsEcN-OMVs could reduce body weight, decrease blood glucose, and increase plasma insulin in obese mice. Similarly, EcN-OMVs treatment could modify the ratio of Firmicutes/Bacteroidetes in the gut, elevate intestinal short-chain fatty acid (SCFA)-producing flora, and influence the SCFA content of the intestine. Furthermore, the intestinal metabolites ornithine and fumaric acid, hepatic ω-6 unsaturated fatty acids, and SCFAs were significantly increased after administering EcN-OMVs.DiscussionOverall, this study showed that EcN-OMVs might act as post-biotic agents that could modulate gut-liver metabolism and ameliorate the pathophysiology of obesity and diabetes

Efficiency enhancement to 24.62% in inverted perovskite solar cells through poly (ionic liquid) bulk modification

Small-molecule ionic liquids (ILs) are frequently employed as efficient bulk phase modifiers for perovskite materials. However, their inherent characteristics, such as high volatility and ion migration properties, pose challenges in addressing the stability issues associated with perovskite solar cells (PSCs). In this study, we design a poly(IL) with multiple active sites, named poly[4-styrenesulfonyl(trifluoromethylsulfonyl)imide]pyridine (P[STFSI][PPyri]), as an efficient additive of perovskite materials. The S=O in the sulfonyl group chelates with uncoordinated Pb2+ and forms hydrogen bonds with the organic cations in the perovskite, suppressing the volatilization of the organic cations. The N+ in pyridine can fix halide ions through electrostatic interaction with I− and Br− ions to prevent halide ion migration. P[STFSI][PPyri] demonstrates the ability to passivate defects and suppress nonradiative recombination in PSCs. Additionally, it facilitates the fixation of organic and halide ions, thereby enhancing the device’s stability and photoelectric performance. Consequently, the introduction of P[STFSI][PPyri] as a dopant in the devices resulted in an excellent efficiency of 24.62%, demonstrating outstanding long-term operational stability, with the encapsulated device maintaining 87.6% of its initial efficiency even after 1500 h of continuous maximum power point tracking. This strategy highlights the promising potential of poly(IL) as an effective additive for PSCs, providing a combination of high performance and stability

Convergence rate of principal component analysis with local-linear smoother for functional data under a unified weighing scheme

The unified weighing scheme for the local-linear smoother in analysing functional data can deal with data that are dense, sparse or of neither type. In this paper, we focus on the convergence rate of functional principal component analysis using this method. Almost sure asymptotic consistency and rates of convergence for the estimators of eigenvalues and eigenfunctions have been established. We also provide the convergence rate of the variance estimation of the measurement error. Based on the results, the number of observations within each curve can be of any rate relative to the sample size, which is consistent with the earlier conclusions about the asymptotic properties of the mean and covariance estimators

A new method for predicting the microvascular invasion status of hepatocellular carcinoma through neural network analysis

Abstract Aims To determine the relationship between microvascular invasion (MVI) and the clinical features of hepatocellular carcinoma (HCC) and provide a method to evaluate MVI status by neutral network analysis. Methods The patients were divided into two groups (MVI-positive group and MVI-negative group). Univariate analysis and multivariate logistic regression analysis were carried out to identify the independent risk factors for MVI positivity. Neural network analysis was used to analyze the different importance of the risk factors in MVI prediction. Results We enrolled 1697 patients in this study. We found that the independent prognostic factors were age, NEU, multiple tumors, AFP level and tumor diameter. By neural network analysis, we proposed that the level of AFP was the most important risk factor for HCC in predicting MVI status (the AUC was 0.704). However, age was the most important risk factor for early-stage HCC with a single tumor (the AUC was 0.605). Conclusion Through the neutral network analysis, we could conclude that the level of AFP is the most important risk factor for MVI-positive patients and the age is the most important risk factor for early-stage HCC with a single tumor

A Predictive Model to Evaluate the HbeAg Positivity of Chronic Hepatitis B Virus Patients in Clinics: A Cross-Sectional Study

Background and Objective: The study aims to investigate the correlation between Hepatitis B ‘e’ antigen (HBeAg) and HBV DNA levels, and to find a convenient tool to estimate the HBV DNA level for clinicians. Materials and Methods: We enrolled 1020 patients in this cross-sectional study and divided them into four groups: an HbeAg-positive and -negative group, and high and low HBV DNA levels groups. Results: Alanine aminotransferase (ALT), Albumin (ALB) and HBeAg are independent risk factors for CHB patients. When the level of HBeAg is higher than 16.15 S/CO, it is four times more likely that the patients will have high levels of HBV DNA than those who do not. The ALT and TB are independent risk factors in HBeAg-negative patients with a high HBV DNA level. We have drawn three predictive models to estimate the HBV DNA levels for those with the chronic hepatitis B virus (CHB), and those that are HBeAg-positive and HBeAg-negative (Y1 = 0.004 × ALT(IU/L) + 1.412 × HBeAg (S/CO) − 0.029 × ALB (g/L) + 0.779, the AUC is 0.672, and the cutoff value is −0.072, there the sensitivity is 0.615, the specificity is 0.648, PPV is 65.182% and NPV is 60.837%; Y2 = 0.007 × HBeAg (S/CO) − 0.016 × HGB (g/L) + 3.070, the AUC is 0.724, and the cutoff value is 1.216, where the sensitivity is 0.626, the specificity is 0.897, PPV is 94.118% and NPV is 34.437%; Y3 = −0.005 × ALT(IU/L) + 0.006 × TB (umol/L) + 0.385, the AUC is 0.661, and the cutoff value is 0.263, where the sensitivity is 0.677, the specificity is 0.587, PPV is 66.820% and NPV is 40.774%, respectively). We propose that HBeAg is the most important risk factor for the patient with a high HBV DNA level, however, it is not as important in the HBeAg-positive group. Conclusions: HBeAg is an independent risk factor that reflects the level of HBV DNA with a strong correlation. Patient with HBeAg (−) should combine TB and ALT to estimate the level of HBV DNA

Key roles of amylopectin synthesis and degradation enzymes in the establishment and reactivation of chronic toxoplasmosis

Abstract Toxoplasma gondii (T. gondii) is an obligate intracellular parasite with a wide range of hosts, including humans and many warm-blooded animals. The parasite exists in two interconvertible forms, namely tachyzoites and bradyzoites in intermediate hosts that are responsible for acute and chronic infections respectively. Mature bradyzoites accumulate large amounts of amylopectin granules but their roles have not been fully characterized. In this study, the predicted key enzymes involved in amylopectin synthesis (UDP-sugar pyrophospharylase, USP) and degradation (alpha-glucan water dikinase, GWD) of ME49 strain were individually knocked out, and then bradyzoite-related phenotyping experiments in vitro and in vivo were performed to dissect their roles during parasite growth and development. Deletion of the usp or gwd gene in the type II strain ME49 reduced the replication rates of tachyzoites in vitro and parasite virulence in vivo, suggesting that amylopectin metabolism is important for optimal tachyzoite growth. Interestingly, the Δusp mutant grew slightly faster than the parental strain under stress conditions that induced bradyzoite transition, which was likely due to the decreased efficiency of bradyzoite formation of the Δusp mutant. Although the Δgwd mutant could convert to bradyzoite robustly in vitro, it was significantly impaired in establishing chronic infection in vivo. Both the Δusp and Δgwd mutants showed a dramatic reduction in the reactivation of chronic infection in an in vitro model. Together, these results suggest that USP and GWD, which are involved in amylopectin synthesis and degradation have important roles in tachyzoite growth, as well as in the formation and reactivation of bradyzoites in T. gondii

Photocatalytic ethylene production by oxidative dehydrogenation of ethane with dioxygen on ZnO-supported PdZn intermetallic nanoparticles

Abstract The selective oxidative dehydrogenation of ethane (ODHE) is attracting increasing attention as a method for ethylene production. Typically, thermocatalysts operating at high temperatures are needed for C–H activation in ethane. In this study, we describe a low temperature ( < 140 °C) photocatalytic route for ODHE, using O2 as the oxidant. A photocatalyst containing PdZn intermetallic nanoparticles supported on ZnO is prepared, affording an ethylene production rate of 46.4 mmol g–1 h–1 with 92.6% ethylene selectivity under 365 nm irradiation. When we employ a simulated shale gas feed, the photocatalytic ODHE system achieves nearly 20% ethane conversion while maintaining an ethylene selectivity of about 87%. The robust interface between the PdZn intermetallic nanoparticles and ZnO support plays a crucial role in ethane activation through a photo-assisted Mars-van Krevelen mechanism, followed by a rapid lattice oxygen replenishment to complete the reaction cycle. Our findings demonstrate that photocatalytic ODHE is a promising method for alkane-to-alkene conversions under mild conditions

Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: protocol for a randomized controlled trial

Abstract Background Our previous randomized controlled trial (RCT) have demonstrated that intermittent Pringle’s maneuver (IPM) with a 25-min ischemic interval can be applied safely and efficiently in open or laparoscopic hepatectomy in patients with hepatocellular carcinoma (HCC) patients. But prolonging the hepatic inflow blocking time will inevitably aggravate the ischemia-reperfusion injury (IRI) caused by systemic response. This RCT aims to evaluate the effect of administration of dexamethasone versus placebo before clamping the hilar pedicle on postoperative liver function, inflammatory response, and perioperative outcomes among HCC patients undergoing liver resection with 25-min hepatic inflow occlusion. Methods and analysis This will be a randomized, dual-arm, parallel-group, double-blinded trial. All eligible and consecutive patients are coming from a regional medical center who are diagnosed with HCC and underwent radical R0/R1 resection. All participates are randomly allocated in dexamethasone group or placebo group. All surgeons, anesthesiologists, and outcome assessors will be blinded to allocation status. Primary endpoints are transaminase-based postoperative hepatic injury on seven consecutive days after surgery and assessed by their peak values as well as area under the curve (AUC) of the postoperative course of aminotransferases. Secondary endpoints are postoperative total bilirubin (TBil), coagulation function, inflammatory cytokines and their respective peaks, intraoperative blood loss, postoperative hospital stay, morbidity, and mortality. The above parameters will be compared using the corresponding statistical approach. Subgroup analysis will be performed according to the liver cirrhosis and major hepatectomy. Discussion Based on our previous study, we will explore further the effect of glucocorticoid administration on attenuating the surgical stress response in order to follow securely 25-min hepatic inflow occlusion. Therefore, the trial protocol is reasonable and the results of the trial may be clinically significant. Trial registration This trial was registered on 3 December 2022, in the Chinese Clinical Trial Registry ( http://www.chictr.org.cn ), ChiCTR2200066381. The protocol version is V1.0 (20221104)